Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year — now down more than 40%. Revenue from its COVID-19 products is down big, and investors are concerned about looming patent cliffs for the business in the years ahead. Let's look at what happened — and Pfizer's prospects for overcoming this latest challenge.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles